CL2025001313A1 - Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas - Google Patents

Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas

Info

Publication number
CL2025001313A1
CL2025001313A1 CL2025001313A CL2025001313A CL2025001313A1 CL 2025001313 A1 CL2025001313 A1 CL 2025001313A1 CL 2025001313 A CL2025001313 A CL 2025001313A CL 2025001313 A CL2025001313 A CL 2025001313A CL 2025001313 A1 CL2025001313 A1 CL 2025001313A1
Authority
CL
Chile
Prior art keywords
methods
same
compositions containing
containing antibody
cleaving enzymes
Prior art date
Application number
CL2025001313A
Other languages
English (en)
Inventor
ELMORE Zachary
Smith Timothy
Hull Joshua
Aravind
Asokan
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of CL2025001313A1 publication Critical patent/CL2025001313A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En el presente documento, se divulgan composiciones para escindir anticuerpos y métodos in vivo para utilizar estas composiciones.
CL2025001313A 2022-11-02 2025-05-02 Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas CL2025001313A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263421996P 2022-11-02 2022-11-02
US202363492985P 2023-03-29 2023-03-29
US202363502920P 2023-05-17 2023-05-17

Publications (1)

Publication Number Publication Date
CL2025001313A1 true CL2025001313A1 (es) 2025-08-29

Family

ID=91196570

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001313A CL2025001313A1 (es) 2022-11-02 2025-05-02 Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas

Country Status (14)

Country Link
EP (1) EP4611795A1 (es)
JP (1) JP2025539722A (es)
KR (1) KR20250117489A (es)
CN (1) CN120500349A (es)
AU (1) AU2023384972A1 (es)
CL (1) CL2025001313A1 (es)
CO (1) CO2025006500A2 (es)
CR (1) CR20250217A (es)
DO (1) DOP2025000104A (es)
IL (1) IL320598A (es)
JO (1) JOP20250098A1 (es)
MX (1) MX2025005078A (es)
PE (1) PE20260130A1 (es)
WO (1) WO2024112492A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202308197D0 (en) * 2023-06-01 2023-07-19 Genovis Ab Protease
WO2025245490A1 (en) * 2024-05-23 2025-11-27 Duke University Compositions comprising antibody cleaving enzymes and methods of use thereof
WO2025256978A1 (en) * 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) * 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
GB202413764D0 (en) * 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses
WO2026093618A1 (en) * 2024-11-04 2026-05-07 F. Hoffmann-La Roche Ag Methods for improving anti-drug antibody assays

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333252B2 (en) * 2010-05-26 2016-05-10 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
EP2949340A1 (en) * 2014-05-30 2015-12-02 IDT Biologika GmbH Vaccine composition against Streptococcus suis infection
US11155585B2 (en) * 2015-07-09 2021-10-26 Intervacc Ab Vaccine against S. suis infection
AR123008A1 (es) * 2020-07-20 2022-10-19 Genentech Inc Métodos para la caracterización de anticuerpos de tipo del medio hacia abajo
US20220133864A1 (en) * 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases

Also Published As

Publication number Publication date
IL320598A (en) 2025-07-01
AU2023384972A1 (en) 2025-05-22
CR20250217A (es) 2025-09-10
EP4611795A1 (en) 2025-09-10
MX2025005078A (es) 2025-09-02
PE20260130A1 (es) 2026-01-16
WO2024112492A1 (en) 2024-05-30
JOP20250098A1 (ar) 2025-04-30
CN120500349A (zh) 2025-08-15
DOP2025000104A (es) 2025-12-15
CO2025006500A2 (es) 2025-08-08
JP2025539722A (ja) 2025-12-09
KR20250117489A (ko) 2025-08-04

Similar Documents

Publication Publication Date Title
CO2025006500A2 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
CL2024003552A1 (es) Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso.
MX2020013347A (es) Polimerasas, composiciones y metodos de uso.
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2024001814A (es) Degradacion enzimatica de polietilentereftalato.
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
ECSP099529A (es) Inhibidores de cinasa mapk/erk
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
AR111835A1 (es) Composiciones estables de inoculantes que comprenden aceites vegetales metilados
MX2008002149A (es) Composiciones de arnt y sus usos.
CO2023015915A2 (es) Anticuerpos anti-ccr8
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
BRPI0517238A (pt) formulações que compreendem ecteinascidina e um dissacarìdeo
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
CO2023014622A2 (es) Conjugados de anticuerpo-fármaco anti-c-met
CO2022000481A2 (es) Inhibidores de enzimas
AR118536A1 (es) Composiciones y métodos para estabilizar formulaciones que contienen proteína
CO2025003362A2 (es) Conjugados de fármacos anticuerpo anti-sez6
BR112022002942A2 (pt) Composição enzimática
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo